Here are four things to know.
1. Buprenophine for opioid use disorder was previously approved to administer in a tablet, dissolving film and implant form. Sublocade provides a new option for patients who may want to reduce the burden of taking a daily tablet.
2. Sublocade is the first monthly injectable buprenophine treatment.
3. The approval comes after an FDA advisory committee voted 18-1 that the injectable drug could benefit addicts.
4. The injection is expected to be available to US patients in the first quarter of 2018.
More articles on supply chain:
FDA: Biotin supplements may interfere with lab tests
Gilead launches hepatitis drug in China at one-fifth the US price
CVS launches ‘real-time benefits’ tool to increase price transparency
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
